42.93
price down icon1.29%   -0.56
pre-market  Pre-market:  44.00   1.07   +2.49%
loading
Merus N V stock is traded at $42.93, with a volume of 599.10K. It is down -1.29% in the last 24 hours and down -18.52% over the past month. Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
See More
Previous Close:
$43.49
Open:
$43.3
24h Volume:
599.10K
Relative Volume:
1.30
Market Cap:
$2.94B
Revenue:
$35.93M
Net Income/Loss:
$-244.56M
P/E Ratio:
-11.42
EPS:
-3.76
Net Cash Flow:
$-157.31M
1W Performance:
-15.71%
1M Performance:
-18.52%
6M Performance:
-1.60%
1Y Performance:
+76.67%
1-Day Range:
Value
$42.30
$43.52
1-Week Range:
Value
$42.30
$51.21
52-Week Range:
Value
$22.26
$61.61

Merus N V Stock (MRUS) Company Profile

Name
Name
Merus N V
Name
Phone
31 030 253 8800
Name
Address
YALELAAN 62, 3584 CM UTRECHT
Name
Employee
229
Name
Twitter
@MerusNV
Name
Next Earnings Date
2024-10-31
Name
Latest SEC Filings
Name
MRUS's Discussions on Twitter

Compare MRUS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
MRUS 42.93 2.94B 35.93M -244.56M -157.31M -3.76
VRTX 451.23 115.74B 10.63B -479.80M -1.35B 13.33
REGN 743.35 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 591.82 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 248.79 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.14 24.49B 3.30B -501.07M 1.03B 11.54

Merus N V Stock (MRUS) Upgrades & Downgrades

Date Action Analyst Rating Change
Nov-02-23 Initiated Canaccord Genuity Buy
Aug-21-23 Initiated TD Cowen Outperform
Aug-02-22 Initiated Stifel Buy
Feb-11-22 Initiated BMO Capital Markets Outperform
Feb-10-22 Initiated Needham Buy
Nov-17-21 Resumed Guggenheim Buy
Jun-07-21 Upgrade Citigroup Neutral → Buy
Apr-08-21 Initiated William Blair Outperform
Mar-16-21 Initiated SVB Leerink Outperform
Jun-26-20 Initiated H.C. Wainwright Buy
May-27-20 Downgrade RBC Capital Mkts Outperform → Sector Perform
Nov-20-19 Resumed Guggenheim Buy
Jun-28-19 Initiated ROTH Capital Buy
Apr-12-19 Resumed Guggenheim Buy
Apr-03-19 Upgrade RBC Capital Mkts Sector Perform → Outperform
Mar-27-19 Initiated Berenberg Buy
Jan-02-18 Downgrade RBC Capital Mkts Outperform → Sector Perform
Sep-15-17 Initiated RBC Capital Mkts Outperform
Mar-21-17 Downgrade Citigroup Buy → Neutral
Dec-22-16 Upgrade Citigroup Neutral → Buy
Nov-07-16 Downgrade Citigroup Buy → Neutral
Jun-13-16 Initiated Citigroup Buy
Jun-13-16 Initiated Guggenheim Buy
Jun-13-16 Initiated Wedbush Outperform
View All

Merus N V Stock (MRUS) Latest News

pulisher
Nov 20, 2024

Merus initiated with a Buy at Goldman Sachs - TipRanks

Nov 20, 2024
pulisher
Nov 20, 2024

Needham & Company LLC Reaffirms Buy Rating for Merus (NASDAQ:MRUS) - MarketBeat

Nov 20, 2024
pulisher
Nov 19, 2024

Merus (NASDAQ:MRUS) Shares Sold by First Turn Management LLC - MarketBeat

Nov 19, 2024
pulisher
Nov 19, 2024

37,426 Shares in Merus (NASDAQ:MRUS) Acquired by State of New Jersey Common Pension Fund D - Defense World

Nov 19, 2024
pulisher
Nov 18, 2024

Merus is Now Oversold (MRUS) - Nasdaq

Nov 18, 2024
pulisher
Nov 18, 2024

GSA Capital Partners LLP Purchases Shares of 13,502 Merus (NASDAQ:MRUS) - MarketBeat

Nov 18, 2024
pulisher
Nov 17, 2024

2,054 Shares in Merus (NASDAQ:MRUS) Purchased by US Bancorp DE - Defense World

Nov 17, 2024
pulisher
Nov 15, 2024

Commodore Capital LP Bolsters Stake in Merus NV - GuruFocus.com

Nov 15, 2024
pulisher
Nov 14, 2024

SAMLYN CAPITAL, LLC Bolsters Stake in Merus NV - GuruFocus.com

Nov 14, 2024
pulisher
Nov 13, 2024

(MRUS) Trading Report - Stock Traders Daily

Nov 13, 2024
pulisher
Nov 13, 2024

Is Merus N.V. (MRUS) Top Performing European Stock Heading into 2025? - MSN

Nov 13, 2024
pulisher
Nov 13, 2024

FMR LLC Bolsters Stake in Merus NV - GuruFocus.com

Nov 13, 2024
pulisher
Nov 12, 2024

10 Top Performing European Stocks Heading into 2025 - Insider Monkey

Nov 12, 2024
pulisher
Nov 11, 2024

Merus (NASDAQ:MRUS) Shares Bought by TimesSquare Capital Management LLC - MarketBeat

Nov 11, 2024
pulisher
Nov 09, 2024

US FDA extends review of Merus' gene-targeting cancer therapy - MSN

Nov 09, 2024
pulisher
Nov 08, 2024

Merus (NASDAQ:MRUS) Given Consensus Recommendation of “Buy” by Brokerages - Defense World

Nov 08, 2024
pulisher
Nov 08, 2024

Merus (NASDAQ:MRUS) Receives $86.70 Consensus Price Target from Brokerages - MarketBeat

Nov 08, 2024
pulisher
Nov 06, 2024

MRUSMerus N.V. Common Shares Latest Stock News & Market Updates - StockTitan

Nov 06, 2024
pulisher
Nov 06, 2024

Merus to Present at Upcoming Investor Conferences - The Manila Times

Nov 06, 2024
pulisher
Nov 05, 2024

Merus Receives FDA extension of PDUFA for zenocutuzumab - GlobeNewswire

Nov 05, 2024
pulisher
Nov 05, 2024

FDA extends review date for Merus' cancer drug Zeno By Investing.com - Investing.com Canada

Nov 05, 2024
pulisher
Nov 05, 2024

FDA extends review date for Merus' cancer drug Zeno - Investing.com India

Nov 05, 2024
pulisher
Nov 05, 2024

Merus (NASDAQ:MRUS) Shares Gap DownHere's Why - MarketBeat

Nov 05, 2024
pulisher
Nov 05, 2024

Merus: Petosemtamab Set Up For December 2024 Data Presentation (NASDAQ:MRUS) - Seeking Alpha

Nov 05, 2024
pulisher
Nov 05, 2024

FDA extends review period for Merus's cancer drug Zeno - Investing.com India

Nov 05, 2024
pulisher
Nov 05, 2024

Merus : FDA Extends Review of Cancer Drug Zenocutuzumab to February - Marketscreener.com

Nov 05, 2024
pulisher
Nov 05, 2024

US FDA extends review of Merus’ gene-targeting cancer therapy - PharmaLive

Nov 05, 2024
pulisher
Nov 05, 2024

Merus says FDA extended review period for cancer drug - MSN

Nov 05, 2024
pulisher
Nov 05, 2024

Merus stock slips as FDA delays drug review (MRUS:NASDAQ) - Seeking Alpha

Nov 05, 2024
pulisher
Nov 05, 2024

FDA extends review period for Merus's cancer drug Zeno By Investing.com - Investing.com Canada

Nov 05, 2024
pulisher
Nov 05, 2024

Harbor Capital Advisors Inc. Buys New Holdings in Merus (NASDAQ:MRUS) - MarketBeat

Nov 05, 2024
pulisher
Nov 04, 2024

abrdn plc Invests $4.36 Million in Merus (NASDAQ:MRUS) - MarketBeat

Nov 04, 2024
pulisher
Nov 02, 2024

Merus N.V. (MRUS) Reports Q3 Loss, Tops Revenue Estimates - MSN

Nov 02, 2024
pulisher
Nov 02, 2024

Merus sees cash runway into 2028 - MSN

Nov 02, 2024
pulisher
Nov 02, 2024

Merus reports Q3 EPS ($1.46), consensus (88c) - MSN

Nov 02, 2024
pulisher
Nov 02, 2024

Merus annonce ses résultats financiers pour le troisième trimestre 2024 et fait le point sur ses activités - GlobeNewswire Inc.

Nov 02, 2024
pulisher
Nov 01, 2024

Merus (NASDAQ:MRUS) Receives "Buy" Rating from Needham & Company LLC - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

Merus N.V. Reports Q3 2024 Financial Results - TipRanks

Nov 01, 2024
pulisher
Oct 31, 2024

Merus falls after updated data for lung cancer therapy - MSN

Oct 31, 2024
pulisher
Oct 31, 2024

Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update - GlobeNewswire

Oct 31, 2024
pulisher
Oct 27, 2024

Novo Holdings A S Increases Position in Merus (NASDAQ:MRUS) - MarketBeat

Oct 27, 2024
pulisher
Oct 26, 2024

Merus (NASDAQ:MRUS) Coverage Initiated at UBS Group - Defense World

Oct 26, 2024
pulisher
Oct 25, 2024

UBS sees upside in Merus stock, highlights potential in head and neck cancer treatment - Investing.com India

Oct 25, 2024
pulisher
Oct 24, 2024

Moody Aldrich Partners LLC Makes New Investment in Merus (NASDAQ:MRUS) - MarketBeat

Oct 24, 2024

Merus N V Stock (MRUS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$71.05
price up icon 0.69%
$18.62
price down icon 6.90%
$36.94
price down icon 0.94%
$364.33
price up icon 1.00%
$194.26
price up icon 3.46%
$102.14
price down icon 4.00%
Cap:     |  Volume (24h):